Melanoma Trial, Recruiting NCT07201376 Sponsor: Dartmouth-Hitchcock Medical Center Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT07201376
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older.
  • People who have been diagnosed with a type of skin cancer called non-melanoma skin cancer, confirmed by a tissue sample test, and are already scheduled to have the growth removed.
  • People with any skin tone (the trial includes a range of skin tones based on a standard skin classification scale).
  • People who are willing and able to follow the study procedures, as determined by the trial team.
  • Women who could become pregnant must have a negative blood pregnancy test taken within 7 days before the study begins (this applies to women who have had at least one period in the past 12 months).
  • People whose skin lesion or growth measures between 5 millimetres and 3 centimetres across.

Who may not be able to join:

  • People under 18 years of age.
  • People who are not able to give informed consent to participate.
  • People with a known allergy to a medication called Ameluz.
  • People who have conditions that cause unusual sensitivity to light, such as photosensitivity or photodermatoses.
  • People with a serious underlying health condition that the investigator believes would make it unsafe or difficult to participate in the study.
  • People with a known sensitivity to porphyrins or to any ingredient in Ameluz, including soya bean phosphatidylcholine.
  • Women who are currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael Chapman, MD, Dartmouth

Phone: 603-653-2209

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 November 2025
Est. completion
1 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Detecting cutaneous malignant lesions using a non-invasive technique

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov